Kyntra Bio (KYNB)
Develops CD46-targeted cancer therapies and roxadustat for anemia in lower-risk myelodysplastic syndromes.
Something off on this page? Send us feedback.
Develops the FG-3246/FG-3180 CD46 program for prostate cancer and roxadustat for anemia in lower-risk myelodysplastic syndromes. Following the sale of its China operation, it is a single biopharmaceutical development business with roxadustat rights divided by territory.
Develops oncology and anemia therapies through a narrowed clinical pipeline. FG-3246, a CD46-targeting antibody-drug conjugate for metastatic castration-resistant prostate cancer, and the related FG-3180 PET biomarker imaging agent form the oncology program in clinical development. A Phase 2 monotherapy dose-optimization study is under way.
After selling the former China roxadustat operation, operates as a single biopharmaceutical development business based in San Francisco. Roxadustat, approved in Europe, Japan, China, and other markets, is being developed for anemia in lower-risk myelodysplastic syndromes. Commercial rights are divided by territory among the company, AstraZeneca, and Astellas; clinical progress depends on ongoing studies and regulatory processes.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 6, 2026 | Oppenheimer | Initiate | Outperform |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $91.3M · Total debt $0 · Total assets $101.1M · Shareholders' equity −$30.1M
- Revenue
- −$1.5M
- Operating income
- −$17.6M
- Net income
- $12.0M
No dividends on record.
| Insiders5 holders · as of Jun 9, 2026 | 2.21% | 89.4K shares | |
| Strategic holders1 holder · as of May 15, 2026 | 9.88% | 400.0K shares | |
| Otherremainder | 87.91% | 3.56M shares |
4.05M company shares as of Sep 3, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCStrategic | 9.88% | 400,000 | 13Gfiled May 15, 2026 ↗ |
James A. SchoeneckInsiderdirector | 0.98% | 39,666 | Form 4filed Jul 2, 2025 ↗ |
Thane WettigInsiderdirector, officer: CEO | 0.67% | 27,005 | Form 4filed Jun 9, 2026 ↗ |
Christine ChungInsiderofficer: SVP, CHINA OPERATIONS | 0.29% | 11,796 | Form 4filed Mar 7, 2025 ↗ |
Juan GrahamInsiderofficer: CHIEF FINANCIAL OFFICER | 0.16% | 6,595 | Form 4filed Dec 9, 2024 ↗ |
| See all 25 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 14, 2026 | Thane Wettig | director, officer: CEO | +5,600 | $7.09 |
| Nov 13, 2025 | Thane Wettig | director, officer: CEO | +1,000 | $9.18 |
| Nov 17, 2025 | Thane Wettig | director, officer: CEO | +2,700 | $9.10 |
- Bristol-Myers Squibb
Approved LR-MDS anemia therapy with broad first-line use
- Novartis (ADR)
Approved radioligand therapy in PSMA-positive mCRPC
- Geron
Approved telomerase inhibitor for transfusion-dependent LR-MDS anemia
- Johnson & Johnson
Approved PARP-inhibitor combination for BRCA-mutated mCRPC
- Pfizer
Approved PARP-inhibitor and ARPI regimen in HRR-mutated mCRPC
- AstraZeneca (ADR)
Approved PARP-inhibitor regimen for BRCA-mutated mCRPC
- Keros Therapeutics
Phase 2 anemia program for lower-risk MDS
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Kyntra Bio | $8.57 | −0.12% | $34.5M | 0.1 | — | 7.5 | −211.3% |
| Bristol-Myers Squibb | $67.50 | −0.23% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Novartis (ADR) | $162.15 | −0.18% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Geron | $1.59 | −0.13% | $1.02B | — | 113.7 | 5.0 | +17.2% |
| Johnson & Johnson | $275.45 | +0.08% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Pfizer | $29.00 | −0.11% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| AstraZeneca (ADR) | $164.21 | +1.58% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Keros Therapeutics | $11.30 | +0.53% | $359.3M | — | — | 23.9 | −99.8% |
| Median | 24.5 | 16.3 | 5.0 | +5.7% |